This cheap biotech offers investors a play on ALS if trial data continues to impress
NeuroSense Therapeutics Ltd.’s stock rose 6.5% Tuesday, as analysts cheered data from the biotech’s late-stage trial of a treatment for the fatal disease amyotrophic lateral sclerosis, or ALS.